PRME

Prime Medicine, Inc. Common Stock

PRME, USA

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

https://primemedicine.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRME
stock
PRME

Market Pulse: Why analysts upgrade PRME stock - Dividend Hike & Accurate Trade Setup Notifications moha.gov.vn

Read more →
PRME
stock
PRME

Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6.4643

Analyst Picks

Strong Buy

6

Buy

2

Hold

4

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.07

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-31.26 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.14 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,880.49 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.38

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 43.23% of the total shares of Prime Medicine, Inc. Common Stock

1.

Alphabet Inc

(8.4491%)

since

2025/06/30

2.

T. Rowe Price Investment Management,Inc.

(3.6375%)

since

2025/06/30

3.

ARK Genomic Revolution ETF

(2.5815%)

since

2025/08/28

4.

BlackRock Inc

(2.5163%)

since

2025/06/30

5.

FMR Inc

(2.1004%)

since

2025/06/30

6.

Vanguard Group Inc

(2.0348%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(1.6723%)

since

2025/07/31

8.

T. Rowe Price Small-Cap Stock

(1.3615%)

since

2025/07/31

9.

T. Rowe Price Small-Cap Value

(1.3354%)

since

2025/07/31

10.

ARK Investment Management LLC

(1.3029%)

since

2025/06/30

11.

ARK Genomic Revolution

(1.272%)

since

2025/06/30

12.

T. Rowe Price U.S. SC Value Eq Tr-D

(1.1916%)

since

2025/06/30

13.

Redmile Group, LLC

(1.1636%)

since

2025/06/30

14.

MWG Management Ltd.

(1.0053%)

since

2025/06/30

15.

Sumitomo Mitsui Trust Group Inc

(0.8944%)

since

2025/06/30

16.

Amova Asset Management Americas, Inc

(0.8914%)

since

2025/06/30

17.

Casdin Capital, LLC

(0.8791%)

since

2025/06/30

18.

Geode Capital Management, LLC

(0.8474%)

since

2025/06/30

19.

iShares Russell 2000 ETF

(0.8021%)

since

2025/08/31

20.

State Street Corp

(0.6952%)

since

2025/06/30

21.

T. Rowe Price Instl Small-Cap Stock

(0.6877%)

since

2025/07/31

22.

Amova ARK Pstv Chg Innovt P JPY Acc

(0.5776%)

since

2025/07/31

23.

Greenwich Wealth Management LLC

(0.4747%)

since

2025/06/30

24.

Schonfeld Strategic Advisors LLC

(0.4591%)

since

2025/06/30

25.

Farallon Capital Management, L.L.C.

(0.4207%)

since

2025/06/30

26.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3914%)

since

2025/07/31

27.

Selectra J. Lamarck Biotech A

(0.3814%)

since

2025/08/31

28.

Morgan Stanley - Brokerage Accounts

(0.3296%)

since

2025/06/30

29.

Fidelity Small Cap Index

(0.3283%)

since

2025/06/30

30.

iShares Biotechnology ETF

(0.3159%)

since

2025/08/31

31.

Citadel Advisors Llc

(0.2925%)

since

2025/06/30

32.

Charles Schwab Investment Management Inc

(0.2909%)

since

2025/06/30

33.

Northern Trust Corp

(0.2873%)

since

2025/06/30

34.

iShares Russell 2000 Value ETF

(0.2839%)

since

2025/08/31

35.

Wanjia Glb Growth IY Hold Alloc (QDII) A

(0.2805%)

since

2025/06/30

36.

Fidelity Extended Market Index

(0.1973%)

since

2025/07/31

37.

Schwab US Small-Cap ETF™

(0.1705%)

since

2025/08/30

38.

Vanguard Russell 2000 ETF

(0.1565%)

since

2025/07/31

39.

Alger LIfe Sciences Innovation Composite

(0.1521%)

since

2025/06/30

40.

CREF Stock R3

(0.1165%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.32

EPS Estimate

-0.43

EPS Difference

0.11

Surprise Percent

25.5814%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.